Valentina Zuco

This study optimizes a subcutaneous xenograft model for EHE using patient-derived cells, showing that low cell densities produce reproducible tumors sensitive to mTOR inhibition.

This study identifies integrin signaling and cell-cycle deregulation as key drivers of SMARCB1-deficient epithelioid sarcoma and highlights therapeutic targets.

This paper identifies HDAC inhibition as a strategy to overcome resistance to EZH2 inhibitors in INI1-deficient epithelioid sarcoma by restoring H3K27 acetylation and enhancing therapeutic response.

The paper identifies ATR as a target for combination EZH2 epigenetic therapy in SMARCB1-deficient sarcomas, showing that EZH2 inhibition promotes DNA damage via PGBD5, and that ATR inhibition enhances therapeutic responses.